Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Video content above is prompted by the following:
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.